Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study | Zendy

Sumit R. Majumdar | Zendy; Robert G. Josse | Zendy; Lin Mu | Zendy; Dean T. Eurich | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Does Sitagliptin Affect the Rate of Osteoporotic Fractures in Type 2 Diabetes? Population-Based Cohort Study

Author(s) -

Sumit R. Majumdar,

Robert G. Josse,

Lin Mu,

Dean T. Eurich

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-4180

Subject(s) - sitagliptin , medicine , type 2 diabetes , hazard ratio , osteoporosis , population , confounding , hip fracture , cohort study , odds ratio , confidence interval , diabetes mellitus , endocrinology , environmental health

Type 2 diabetes and osteoporosis are both common, chronic, and increase with age, whereas type 2 diabetes is also a risk factor for major osteoporotic fractures (MOFs). However, different treatments for type 2 diabetes can affect fracture risk differently, with metaanalyses showing some agents increase risk (eg, thiazolidinediones) and some reduce risk (eg, sitagliptin).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research